NasdaqGS - Delayed Quote • USD
Amphastar Pharmaceuticals, Inc. (AMPH)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 6:26 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 0.78 | 0.8 | 3.62 | 4.32 |
| Low Estimate | 0.72 | 0.7 | 3.12 | 3.4 |
| High Estimate | 0.84 | 0.87 | 3.98 | 5.11 |
| Year Ago EPS | 0.62 | 0.65 | 3.32 | 3.62 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 175.05M | 181.08M | 776.96M | 813.63M |
| Low Estimate | 165.5M | 167.9M | 741M | 574M |
| High Estimate | 186M | 195M | 813.42M | 891M |
| Year Ago Sales | 134.16M | 145.71M | 644.39M | 776.96M |
| Sales Growth (year/est) | 30.50% | 24.30% | 20.60% | 4.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.47 | 0.56 | 0.69 | 0.93 |
| EPS Actual | 0.62 | 0.65 | 1.15 | 0.88 |
| Difference | 0.15 | 0.09 | 0.46 | -0.05 |
| Surprise % | 31.90% | 16.10% | 66.70% | -5.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.78 | 0.8 | 3.62 | 4.32 |
| 7 Days Ago | 0.79 | 0.83 | 3.74 | 4.32 |
| 30 Days Ago | 0.79 | 0.83 | 3.76 | 4.33 |
| 60 Days Ago | 0.68 | 0.75 | 3.71 | 4.09 |
| 90 Days Ago | 0.68 | 0.75 | 3.71 | 4.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | AMPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.80% | -- | -- | 1.60% |
| Next Qtr. | 23.10% | -- | -- | 10.50% |
| Current Year | 9.00% | -- | -- | 5.20% |
| Next Year | 19.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 22.60% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 66.53% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Needham: Hold | 4/10/2024 |
| Initiated | JP Morgan: Overweight | 3/5/2024 |
| Initiated | B of A Securities: Neutral | 11/17/2023 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 5/17/2023 |
| Maintains | Piper Sandler: Overweight | 10/25/2022 |
| Initiated | Capital One: Overweight | 7/29/2022 |
Related Tickers
ALKS Alkermes plc
23.85
+0.38%
COLL Collegium Pharmaceutical, Inc.
34.84
+0.20%
NBIX Neurocrine Biosciences, Inc.
132.00
-0.41%
LNTH Lantheus Holdings, Inc.
63.81
+2.37%
EGRX Eagle Pharmaceuticals, Inc.
4.6100
+2.90%
ANIP ANI Pharmaceuticals, Inc.
65.48
+1.39%
DERM Journey Medical Corporation
3.4800
-2.79%
AMRX Amneal Pharmaceuticals, Inc.
5.42
+1.12%
CTLT Catalent, Inc.
55.48
-0.57%
LFCR Lifecore Biomedical, Inc.
6.69
+5.94%